Rhenman & Partners Asset Management AB Purchases 7,000 Shares of IQVIA Holdings Inc. $IQV

Rhenman & Partners Asset Management AB raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 35.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 26,500 shares of the medical research company’s stock after acquiring an additional 7,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in IQVIA were worth $5,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA in the fourth quarter valued at $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at $27,000. Activest Wealth Management grew its position in shares of IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of IQVIA in the fourth quarter valued at $35,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $181.10 on Friday. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The business has a 50-day simple moving average of $173.56 and a 200 day simple moving average of $193.68. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $30.23 billion, a price-to-earnings ratio of 22.44, a PEG ratio of 1.55 and a beta of 1.21.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the business earned $2.70 earnings per share. The firm’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on IQV shares. Morgan Stanley set a $225.00 price target on IQVIA in a research report on Thursday, May 7th. Truist Financial reduced their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday, March 6th. Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.